TCBP - TCBP Plans to Acquire NK Platform Technologies

2024-04-04 08:52:12 ET

DENVER, Colo., Apr 04, 2024 ( 247marketnews.com )- TC BioPharm (NASDAQ: TCBP )  executed a non-binding letter of intent with a company that covers the proprietary manufacturing process of two allogeneic CAR-NK therapeutics, both of which TCB believes are valuable as monotherapies as well as in conjunction with TCB-008 in the future, as part of TCB’s M&A strategy aimed at expanding its therapeutic platform and leveraging NK cells in treating both solid tumors and other indications.

“With the difficult times in cell therapy we see this as a unique opportunity to aggressively expand our asset base in other immune cells and immune responder technologies, which we believe will further enhance TCBP as a leader in cell therapy and increase our future value,” said Mr. Bryan Kobel, CEO of TC BioPharm. “We believe this proposed asset acquisition brings not just a new and expanded opportunity in cancer, but synergies in combination efforts with TCB-008 in numerous indications.  This proposed asset acquisition would leverage our strengths in optimizing manufacturing processes and developing new cell therapies rapidly to the clinical stage, as well as our core asset on asset base expansion and combination efforts with TCB-008. By merging complimentary technologies under one roof we believe the potential exit value of TCBP is increased, patients will benefit in expanded clinical trial efforts which we will control, and ultimately benefit shareholders in future value.”

The post TCBP Plans to Acquire NK Platform Technologies appeared first on 24/7 MarketNews .

For further details see: